The reports of 2 phase II clinical trials that investigated Namodenoson in patients with MASH27 or HCC26 were based on the assumption that ADORA3 should be overexpressed in inflammatory or tumor tissues compared to healthy tissues. This evidence concerns the gene ADORA3 and neoplasm.